期刊文献+

132例胃的胃肠间质瘤治疗及预后分析 被引量:19

Analysis of treatment and prognosis in 132 patients with gastric gastrointestinal stromal tumors
原文传递
导出
摘要 目的 探讨胃的胃肠间质瘤(GIST)临床病理特点和治疗及影响预后的因素.方法 回顾性分析1998年1月至2008年12月天津医科大学附属肿瘤医院收治的经手术治疗的132例胃GIST患者的临床病理资料,并比较不同因素对预后的影响.结果 本组患者病变部位:胃底贲门50例(37.9%),胃体62例(47.0%),胃窦部13例(9.8%),占据胃壁两个部位6例(4.5%),胃弥漫肿物1例(0.8%);肿瘤平均直径9.4(1.0~27.0)cm.全组患者均行肿瘤完整切除,有41例联合脏器切除,淋巴结清扫34例,未发现转移淋巴结.免疫组织化学染色,CD117阳性率93.2%(123/132),CD34阳性率82.6%(109/132).118例获随访患者的1、3、5年生存率分别为94.7%、80.2%和56.6%.单因素分析显示,Fletcher分级、肿瘤大小、肿瘤侵犯其他脏器、转移和口服甲磺酸伊马替尼对生存率有影响(P<0.05,P<0.01);多因素分析显示,Fletcher分级、肿瘤转移、口服甲磺酸伊马替尼是预后的独立影响因素(P<0.05).结论 转移是影响胃GIST预后的独立危险因素,Fletcher分级是判断胃GIST生物学行为及预后简单有效的方法;手术是治疗胃GIST的主要方法,靶向治疗能进一步改善胃GIST患者的预后. Objective To investigate the clinicopathological characteristics, diagnosis, treatment and prognostic factors of gastric gastrointestinal stromal tumors (GIST) in the stomach. Methods The clinicopathological data of 132 patients with gastric GIST between January 1998 and December 2008 were analyzed retrospectively, and the prognostic factors were evaluated. Results Tumor locations were the cardia or fundus(50, 37.9%), the stomach body(62, 47%),the antrum(13, 9.8%), and two regions were found in 6 cases(4.5%), three regions in 1 cases(0.8%). Tumor size ranged from 1.0 to 27.0 cm with an average of 9.4 cm. All the patients underwent complete tumor resection, including multi-organ resection in 41 cases. Thirty-four cases underwent lymph node dissection. All the lymph nodes were negative. The positive rate was 93.2%( 123/132) for CD 117 and 82.6%(109/132) for CD34. The 1-,3- and 5-year survival rates of the 118 cases with follow up were 94.7%, 80.2%, and 56.6% , respectively. Univariate analysis revealed that the differences in Fletcher classification, tumor size, infiltration to surrounding tissue, preoperative metastasis, and adjuvant postoperative therapy with imatinib were related to the survival rates. Multivariate analysis demonstrated that Fletcher classification, preoperative metastasis and adjuvant postoperative therapy with imatinib were independent poor prognostic factors for survival. Conclusions Preoperative metastasis is an independent factor predicting poor prognosis of gastric GIST. Fletcher classification can be used to evaluate the biological behaviors and prognosis, while surgery is the main therapy and targeted therapy can improve survival of gastric GIST.
出处 《中华胃肠外科杂志》 CAS 北大核心 2010年第7期492-496,共5页 Chinese Journal of Gastrointestinal Surgery
关键词 胃肠间质瘤 外科手术 预后 甲磺酸伊马替尼 Gastrointestinal stromal tumors, stomach Surgical procedures Prognosis Imatinib mesylate
  • 相关文献

参考文献14

  • 1Cichoz-Lach H,Kasztelan-Szczerbinska B,Slomka M.Gastrointestinal stromal tumors:epidemiology,clinical picture,diagnosis,prognosis and treatment.Pol Arch Med Wewn,2008,118(4):216-221.
  • 2Fletcher CD,Berman JJ,Corless C,et al.Diagnosis of gastrointestinal stromal tumors:A consensus approach.Hum Pathol,2002,33(5):459-465.
  • 3Bauer S,Corless CL,Heinrich MC,et al.Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.Cancer Chemother Pharmacol,2003,51(3):261-265.
  • 4戎龙,万远廉,年卫东,柳萍,梁进雨.胃间质瘤63例临床分析[J].中华胃肠外科杂志,2009,12(1):24-27. 被引量:11
  • 5Mochizuki Y,Kodera Y,Ito S,et al.Treatment and risk factors for recurrence after curative resection of gastrointestinal stromal tumors of the stomach.World J Surg,2004,28(9):870-875.
  • 6Carboni F,Carlini M,Scardamaglia F,et al.Gastrointestinal stromal tumors of the stomach.A ten-year surgical experience.JExp Clin Cancer Res,2003,22(3):379-384.
  • 7DeMatteo RP,Lewis JJ,Leung D,et al.Two hundred gastrointestinal stromal tumors:recurrence patterns and prognostic factors for survival.Ann Surg,2000,231 (1):51-58.
  • 8Croom KF,Perry CM.Imatinib mesylate:in the treatment of gastrointestinal stromal tumours.Drugs,2003,63(5):513-524.
  • 9Miettinen M,Sobin LH,Lasota J.Gastrointestinal stromal tumors of the stomach:a clinicopathologic,immunohistochemical,and molecular genetic study of 1765 cases with long-term follow-up.Am J Surg Pathol,2005,29(1):52-68.
  • 10白月奎,邵永孚,石素胜,高燕宁,孙耘田,程书钧,刘秀云.胃肠道间质瘤预后多因素分析[J].中华肿瘤杂志,2005,27(10):598-601. 被引量:22

二级参考文献43

  • 1娄越亮,陈华,张燮良,战忠利.96例胃肠道间质瘤临床诊治分析[J].中华肿瘤杂志,2004,26(7):437-439. 被引量:25
  • 2何裕隆.胃肠间质瘤外科治疗的选择[J].中华胃肠外科杂志,2006,9(1):15-16. 被引量:28
  • 3詹文华,王鹏志,邵永孚,伍晓汀,顾晋,李荣,万德森,丁克峰,师英强,于吉人,卢辉山,邹小明,毕建威,孙益红,陆云飞,陈道达,张信华.伊马替尼术后辅助治疗胃肠间质瘤的多中心前瞻性临床试验中期报告[J].中华胃肠外科杂志,2006,9(5):383-387. 被引量:85
  • 4Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol, 2005, 16:566-578.
  • 5Parfitt JR, Streutker C J, Riddell RH, et al. Gastrointestinal stromal tumors: a contemporary review. Pathol Res Pract, 2006, 202 : 837-847.
  • 6Fusaroli P, EK, R.N.A.L.D, et al. Gastrointestinal stromal tumors: Long term follow up by EUS up to 13 years. Digestive and Liver Disease, 2002, 34 : A116.
  • 7Dematteo RP, Heinrich MC, El-Rifai WM, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol, 2002, 33:466-77.
  • 8Demetri GD, yon Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347:472-480.
  • 9Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol, 1983, 7:507-519.
  • 10Tran T, Davila JA, E1-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol, 2005, 100: 162-168.

共引文献113

同被引文献215

引证文献19

二级引证文献75

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部